Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Dual antiplatelet therapy (DAPT) is crucial for acute coronary syndrome (ACS) patients, preventing ischemic events.
• However, DAPT significantly elevates bleeding risk, a major cause of morbidity and mortality.
• Effective bleeding risk management is vital throughout the patient's clinical journey.

Purpose of the Study:

• To provide a clinically oriented, patient-tailored approach for reducing bleeding risk in ACS patients on DAPT.
• To outline strategies for managing bleeding complications in this patient population.
• To analyze clinical decision-making steps from ACS diagnosis through long-term follow-up.

Main Methods:

• Review of current literature and clinical guidelines on DAPT in ACS.
• Analysis of decision-making processes for bleeding risk management.
• Description of emerging treatment strategies for DAPT safety enhancement.

Main Results:

• Bleeding risk is an inherent complication of DAPT in ACS.
• Timely and tailored therapeutic adjustments are critical for managing bleeding risk.
• Newer strategies aim to improve DAPT safety profiles.

Conclusions:

• A patient-centered approach is essential for optimizing DAPT in ACS, balancing ischemic prevention with bleeding risk reduction.
• Comprehensive management strategies are needed throughout the patient's care continuum.
• Ongoing research into safer DAPT protocols is crucial for improving patient outcomes.